Similar articles

• Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus.

  Reidenberg MM, Drayer DE. Reidenberg MM, et al. Angiology. 1986 Dec;37(12 Pt 2):968-71. Angiology. 1986. PMID: 2433971
• Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide.

  Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg MM. Lahita R, et al. N Engl J Med. 1979 Dec 20;301(25):1382-5. doi: 10.1056/NEJM197912203012506. N Engl J Med. 1979. PMID: 91972 No abstract available.
• Alter drug structure--avert induced lupus.

  González ER. González ER. JAMA. 1981 Oct 9;246(15):1634. JAMA. 1981. PMID: 6168781 No abstract available.
• Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.

  Atkinson AJ Jr, Ruo TI, Piergies AA. Atkinson AJ Jr, et al. Angiology. 1988 Jul;39(7 Pt 2):655-67. Angiology. 1988. PMID: 2457345 Review.
• Procaine amide-induced systemic lupus erythematosus.

  Baker H, Moore-Robinson M. Baker H, et al. Br J Dermatol. 1970 Mar;82(3):320-1. Br J Dermatol. 1970. PMID: 4909793 Review. No abstract available.